Cargando…
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
The novel coronavirus SARS-CoV2, which causes COVID-19, has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plas...
Autores principales: | Clark, Natasha M, Janaka, Sanath Kumar, Hartman, William, Stramer, Susan, Goodhue, Erin, Weiss, John, Evans, David T., Connor, Joseph P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452094/ https://www.ncbi.nlm.nih.gov/pubmed/34545365 http://dx.doi.org/10.1101/2021.09.14.460394 |
Ejemplares similares
-
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
por: Clark, Natasha M., et al.
Publicado: (2022) -
A Case of IgG and IgA Anti-Laminin-332 Antibody-Positive Mucous Membrane Pemphigoid with IgG and IgA Anti-Envoplakin and Anti-Periplakin Antibodies
por: Matsushima, Yoshiaki, et al.
Publicado: (2022) -
Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model
por: Lueangsakulthai, Jiraporn, et al.
Publicado: (2020) -
Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy
por: Zhao, Yan-feng, et al.
Publicado: (2017) -
IgG, IgM and IgA antibodies against the novel polyprotein in active tuberculosis
por: Feng, Xiaoyan, et al.
Publicado: (2014)